Categories: News

ADM Tronics Reports First Quarter of Fiscal Year 2025 Results

NORTHVALE, NJ / ACCESSWIRE / August 19, 2024 / ADM Tronics Unlimited, Inc. (OTCQB:ADMT), a technology-based developer and manufacturer of innovative technologies and products, announces results for its first fiscal quarter ended June 30, 2024 of Fiscal Year 2025.

ADMT achieved a profit for the first quarter of Fiscal Year 2025, as compared to loss for the same period last year. Revenues increased over 12% for the quarter ended June 30, 2024, as compared to the same period last year. Profit from operations was $164,281 for the quarter ended June 30, 2024 as compared to a loss from operations of $137,796 for the quarter ended June 30, 2023. Net profit was $272,168 for the quarter ended June 30, 2024 as compared to net loss of $132,261 for the same period last year.

ADMT completed R&D and engineering efforts of its’ Vet-Sonotron ® non-invasive pain treatment device for the veterinary market during the last quarter of fiscal year ended March 31, 2024. (www.vet-sonotron.com) The Company then directed additional R&D and engineering activities to advance the development of the human medical version of this innovative therapeutic technology. As a result, R&D expense for the quarter ended June 30, 2024 was comparable to the same period last year. The Company plans on pursuing a 510(k) submission to the FDA when development of the human medical version is completed. The Sonotron ® is being developed for use on humans where the need for effective pain treatment without the use of drugs or opioids is very large and unmet.

Revenues for the quarter ended June 30, 2024, were $857,845 as compared to $762,689 for the same period last year, an increase of 12%. Income from operations for June 30, 2024 increased approximately 119% to $164,281 as compared to loss of $137,796 for the same period last year. Complete financial results are available in the Company’s Quarterly Report on Form 10Q for June 30, 2024, available at www.sec.gov.

Financial Highlights

Three Months Ended

Three Months Ended

June 30, 2024

June 30, 2023

Net Revenues

$

857,845

$

762,689

Cost of sales

336,942

437,547

Gross Profit

520,903

325,142

Operating expenses:
Research and development

127,993

130,587

Selling, general and administrative

228,629

332,351

Total operating expenses

356,622

462,938

Profit (loss) from operations

164,281

(137,796

)

Total other income

108,387

5,535

Profit (loss) before provision for income taxes

272,668

(132,261

)

Total benefit (provision) for income taxes

500

Net profit (loss)

$

272,168

$

(132,261

)

Basic and diluted earnings (loss) per common share

$

0.00

$

(0.00

)

Weighted average shares of common stock outstanding – basic and diluted

67,588,492

67,588,492

About ADMT

ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house. ADMT has three areas of activity: Proprietary Electronic Medical Devices; Design, Engineering, Regulatory and Manufacturing Services; and, Eco-Friendly, Safe, Water-Based Formulations. The Company’s headquarters, laboratories, and FDA-Registered medical device manufacturing operations are located in Northvale, NJ. ADMT’s multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure, for the research, development and commercialization of diversified technologies. Additional information is available at admtronics.com

ADMT welcomes inquiries for its electronics and medical device contract engineering and manufacturing services at www.admteng.com.

To receive ADMT email updates, complete form at https://admtronics.com/investor-relations/

Sonotron ® is a registered trademark of ADM Tronics Unlimited, Inc.

Except for historical information contained herein, the matters set forth in this news release are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance. Although ADMT believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT’s filings with the SEC, news releases and other communications. The Company assumes no obligation to update the information contained in this news release.

For more information – Investor Relations:

Howard Isaacs 562-987-4939 HISAACS@EARTHLINK.NET

Richard Cavalli 303-956-1777 RICHARDACAVALLI@GMAIL.COM

SOURCE: ADM Tronics Unlimited Inc.

View the original press release on accesswire.com

Staff

Recent Posts

University Lab Partners Announces the Winners of Orange County’s 2024 Pitch. Launch. Grow. Competition

IRVINE, Calif., Aug. 19, 2024 /PRNewswire/ -- University Lab Partners (ULP) is proud to announce…

9 hours ago

Waystar Wins Stevie® Awards for Company of the Year and AI Solutions in Healthcare

Company awarded several distinctions for healthcare payments software at 2024 International Business Awards® LEHI, Utah…

9 hours ago

Agilisium Recognized as a Leader in Everest Group Life Sciences Digital Services for Mid-Market Enterprises PEAK Matrix®Report

LOS ANGELES, Aug. 19, 2024 /PRNewswire/ -- Agilisium, a premier digital innovations partner for Life Sciences…

9 hours ago

Sustainable Agriculture: The Growing Need for Biotech Innovations in the World’s Food Supplies

USA News Group Commentary Issued on behalf of BioVaxys Technology Corp. VANCOUVER, BC, Aug. 19,…

9 hours ago

ABLE United Marks $100 Million Savings Milestone on Inaugural National ABLE Savings Day

Florida's ABLE program reaches a major milestone, empowering individuals with disabilities and their families to…

9 hours ago

Applied DNA To Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I

STONY BROOK, NY / ACCESSWIRE / August 19, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN)…

9 hours ago